News | August 05, 2025
Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Subscribe To Our Newsletter & Stay Updated
